Skip to main content
A person holding a notebook speaks into a microphone

Industry Liaison Forum

The Industry Liaison Forum was established in 2001 to promote and facilitate the full contribution of the biomedical industry to the global HIV response. It does this by catalysing multi-stakeholder dialogue, engagement and action to address barriers along the HIV prevention, diagnosis and care continuum. Its members are from industry (originator and generic biopharmaceutical, diagnostic and other health-technology companies) and non-industry organizations. They share a wealth of perspectives, expertise and knowledge to contribute together to the HIV response.

The Forum’s strategic plan for 2020-2023 highlights its commitment to further build on its unique neutrality, convening power, multi-stakeholder composition and rules of engagement to strengthen its contribution to the HIV response. To achieve this, it:

  • Engages and grows membership by continuing to be a cross-stakeholder, neutral, safe-space platform that actively expands and engages its membership base to foster connections, dialogue and action.
  • Accelerates priority areas by addressing barriers along the HIV prevention, diagnosis and care continuum.
  • Publishes and promotes members’ perspectives to advance the global HIV response.

Interested in joining? Please contact

Case Studies

Case study 1: The GAP-f
The Global Accelerator for Paediatric Formulations (GAP-f) resulted from collaboration between members of the Forum, the IAS Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) and the World Health Organization (WHO). Corporate partners working with international stakeholders steered the agenda and efforts to create GAP-f.

alternative text

Case study 2: Manufacturers’ perspective on WHO PQDx
Industry partners’ perspectives on WHO Prequalification of In Vitro Diagnostics (WHO PQDx) were collated and published in Clinical Infectious Diseases.

alternative text

Case study 3: Policy brief on innovative digital technologies
Corporate partners and international stakeholders reviewed learnings from the COVID-19 response to recommend a set of innovative technologies that should be scaled up for better HIV prevention and treatment.

alternative text

Meet the Forum members


  • Anton Pozniak, Chelsea & Westminster NHS Trust, United Kingdom
  • Helen McDowell, ViiV Healthcare, United Kingdom

Civil Society

  • Brent Allan, International Public Health consultant with the IAS, ASHM and ICASO, Australia
  • Rehab Mwaniki, National Empowerment Network of People Living with HIV/AIDS (NEPHAK), Kenya
  • Wim Vandevelde, Global Network of People living with HIV (GNP+), South Africa


  • Boniface Dongmo Nguimfack, WHO, Switzerland
  • Catherine Hankins, Amsterdam Institute for Global Health and Development (AIGHD), The Netherlands
  • Colleen Daniels, Harm Reduction International, United Kingdom
  • Elliot Cowan, Partners in Diagnostics, USA
  • Yodit Belew, FDA, USA
  • Martin Auton, Global Fund, Switzerland
  • Ray Corrin, WHO PQ, Switzerland
  • Nicholas Hellmann, Elizabeth Glaser Pediatric AIDS Foundation, USA
  • Carmen Perez Casas, UNITAID, Switzerland
  • Sandeep Juneja, TB Alliance, Switzerland
  • Sandra Nobre, Medicines Patent Pool, Switzerland


  • Donna Fromhold, Janssen, USA
  • Duncan Blair, Abbott, Switzerland
  • Joanna Sickler, Roche Molecular Systems, USA
  • Beverly Goede, Roche Molecular Systems, USA
  • Emily Gibbons, MSD, USA
  • Helen McDowell, ViiV Healthcare, USA
  • Jim Rooney, Gilead Sciences, USA
  • Tony Boova, Beckman Coulter, USA

Ex-officio – International AIDS Society

  • Adeeba Kamarulzaman, IAS President
  • Birgit Poniatowski, IAS Executive Director
  • Carole Beilleau, IAS Director, Development and Partnerships
  • Nelli Barrière, IAS Project Manager, Corporate Partnership Programme